Pfizer is fattening its drug portfolio by betting that more people will want to slim down. The New York drugmaker announced Monday that it’s acquiring Metsera, and its portfolio of four medications for obesity and cardiometabolic diseases, in a deal valued at as much as $7.3 billion.

In addition to potential future payments tied to specific clinical and regulatory milestones, Pfizer said it will acquire all outstanding shares of Metsera stock for $47.50 per share. Metsera shares closed at $33.32 on Friday and surged more than 60% on Monday to as high as $54.47 per share. New York-based Metsera emerged from stealth mode last year to take on the weight-loss market and completed its initial public offering earlier this year.

The acquisition, which has been unanimously approved by the boards

See Full Page